KYORIN Holdings, Inc. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2015; Announces Dividend for the Second Quarter of Fiscal 2016, Payable on December 4, 2015; Revises Dividend for the Year End Ending March 31, 2016; Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2016
November 04, 2015
Share
KYORIN Holdings, Inc. reported consolidated earnings results for the six months ended September 30, 2015. For the six months, the company reported consolidated net sales of JPY 52,386 million, operating income of JPY 4,099 million, ordinary income of JPY 4,266 million, profit attributable to owners of parent of JPY 2,967 million or JPY 40.10 per diluted share, compared to net sales of JPY 51,112 million, operating income of JPY 4,587 million, ordinary income of JPY 4,898 million, profit attributable to owners of parent of JPY 3,495 million or JPY 46.78 per diluted share, a year ago.
The company announced dividend of JPY 20.00 per share for the second quarter of fiscal 2016, compared to JPY 20.00 per share a year ago. The dividend will be payable on December 4, 2015.
The company revised dividend guidance of JPY 32.00 per share for the year end ending March 31, 2016, compared to JPY 32.00 per share, a year ago.
The company provided consolidated earnings guidance for the full year ending March 31, 2016. For the full year, the company is forecasting its net sales of JPY 120,200 million, operating income of JPY 16,000 million, ordinary income of JPY 16,300 million, profit attributable to owners of parent of JPY 11,500 million or JPY 155.51 per share.
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
KYORIN Holdings, Inc. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2015; Announces Dividend for the Second Quarter of Fiscal 2016, Payable on December 4, 2015; Revises Dividend for the Year End Ending March 31, 2016; Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2016
KYORIN PHARMACEUTICAL CO., LTD. 
